Tengfei Creation Center,55 Jiangjun Avenue, Jiangning District,Nanjing admin@sinochem-nanjing.com 3389378665@qq.com
Follow us:

Donepezil Benzyl Bromide Hydrochloride

    • Product Name Donepezil Benzyl Bromide Hydrochloride
    • Alias donepezil-benzyl-bromide-hydrochloride
    • Mininmum Order 1 g
    • Factory Site Tengfei Creation Center,55 Jiangjun Avenue, Jiangning District,Nanjing
    • Price Inquiry admin@sinochem-nanjing.com
    • Manufacturer Sinochem Nanjing Corporation
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    322979

    Chemical Name Donepezil Benzyl Bromide Hydrochloride
    Molecular Formula C24H30BrClNO3
    Molecular Weight 494.87 g/mol
    Appearance White to off-white powder
    Solubility Soluble in water and methanol
    Purity ≥98% (HPLC)
    Storage Temperature 2-8°C
    Cas Number 1200130-79-9
    Synonyms Donepezil Benzyl Bromide HCl
    Application Research chemical; intermediate
    Stability Stable under recommended storage conditions
    Hazard Class Irritant
    Usage For laboratory use only

    As an accredited Donepezil Benzyl Bromide Hydrochloride factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing
    Shipping
    Storage
    Application of Donepezil Benzyl Bromide Hydrochloride

    Applications of Donepezil Benzyl Bromide Hydrochloride in Industrial Manufacturing

    Donepezil Benzyl Bromide Hydrochloride, manufactured at our GMP-compliant plant, plays a critical role as an advanced pharmaceutical intermediate in several high-precision industrial synthesis lines. Below are the principal downstream application scenarios where our material integrates into established formulation processes, adhering to rigorous quality, safety, and regulatory requirements.

    1. Active Pharmaceutical Ingredient (API) Synthesis for Alzheimer’s Medications

    Pharmaceutical companies harness this compound in the key quaternization step for the industrial-scale production of Donepezil Hydrochloride, the widely used anti-Alzheimer’s API. In this process, careful stoichiometric control ensures accurate benzylation, which is essential for achieving the necessary purity for subsequent crystallization and formulation stages. Process engineers determine input ratios based on batch output requirements, with precise in-line monitoring to meet pharmacopoeial specifications for residual impurities and particle size. The downstream manufacturing integrates our product directly into the advanced synthesis step before the main purification operations.

    Industry compliance standards

    • ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
    • United States Pharmacopeia (USP)
    • European Pharmacopoeia (Ph. Eur.)
    • China Pharmacopoeia (ChP)

    Typical usage ratio

    • Reaction molar ratio typically 1:1.05 to substrate, adjustable for yield optimization and impurity control.

    Downstream process integration

    • Input at the benzylation/quaternization reaction stage during API core formation.
    • Post-reaction monitoring for completion, prior to solvent extraction and crystallization.
    • Preformulation assessment for residual bromide and purity.

    Final product types

    • Donepezil Hydrochloride API
    • Tablet and tablet intermediate blends for anti-Alzheimer’s drugs
    • Film-coated or orally disintegrating dosage forms
    • Bulk API for international formulation partners

    2. Research-Grade Intermediate for CNS Drug Development

    In contract research organizations and specialty pharma labs, synthetic chemists rely on this raw material for generating quaternary ammonium intermediates in early-stage CNS (central nervous system) compound libraries. Accurate metering and batch documentation ensure that experimental reaction monitoring aligns with GLP requirements. The compound supports scale development, impurity profile mapping, and pilot batch validation for investigational therapies, making it integral for process transfer and analytical method development in clinical candidate pipelines.

    Industry compliance standards

    • OECD Principles of Good Laboratory Practice (GLP)
    • FDA 21 CFR Part 211 (where applicable to investigational drugs)
    • ISO/IEC 17025 laboratory accreditation

    Typical usage ratio

    • Substrate to intermediate ratio from 1:1.1, adjusted for lab-scale upscaling and parallel synthesis methods.

    Downstream process integration

    • Input as key intermediate for CNS lead analogue series.
    • Used in small-scale reactors or combinatorial synthesis batches.
    • Facilitates NMR and chromatographic purification studies.

    Final product types

    • Research grade CNS intermediates
    • Screening compounds for neuroprotective candidate assessment
    • Pilot drug substances for preclinical evaluation

    3. Custom Synthesis for API CDMO Services

    Custom API manufacturing operations within contract development and manufacturing organizations (CDMOs) use our material as a controlled input for tailor-made quaternized intermediates, contracted under mutual confidentiality terms. The input ratio and purity are fine-tuned depending on client process documentation and regulatory filings, ensuring traceability for clients conducting DMF submissions in major market jurisdictions. Batch release occurs only after in-process control and compliance verification, forming the basis for downstream micronization or granulation as specified in the master batch record.

    Industry compliance standards

    • US FDA cGMP (21 CFR Parts 210, 211)
    • EU GMP Guide Part II – Basic Requirements for Active Substances
    • ICH Q11: Development and Manufacture of Drug Substances
    • ISO 9001:2015 Quality Management Systems

    Typical usage ratio

    • Custom ratio specified per CDMO process route; typically 1:1.02 to 1:1.10 to accommodate client impurity tolerance and yield forecasts.

    Downstream process integration

    • Positioned in multi-step synthesis as designated by client’s route of synthesis (RoS).
    • Subject to in-process control (IPC) at each step; full traceable documentation provided.
    • Staged for downstream granulation or micronization prior to further transformation or shipment.

    Final product types

    • Non-commodity NCE (new chemical entity) intermediates
    • Client-specific drug precursor substances
    • Microgranules or micronized custom intermediates

    4. Analytical Method Development Reference Material

    Certified analytical laboratories employ this compound as a reference standard in the development and validation of HPLC, LC-MS, and NMR analytic methods to quantify API-related impurities in finished drug products. Calibrators and control solutions prepared with verified purity batches support method transfer to quality control laboratories at partner pharma plants. All usage aligns with documented sample preparation protocols, ensuring consistency and repeatability across analytical campaigns subject to regulatory inspection.

    Industry compliance standards

    • USP General Chapter <1225> Validation of Compendial Procedures
    • Ph. Eur. 2.2.46 Chromatographic Separation Techniques
    • ICH Q2(R1): Validation of Analytical Procedures

    Typical usage ratio

    • Reference solution concentration typically 10–100 µg/mL; adjusted according to detection method, linearity range, and LOD/LOQ validation steps.

    Downstream process integration

    • Used in calibration curves for method validation.
    • Spiked into real or placebo matrices to assess matrix effect, recovery, and robustness studies.
    • Supports transfer protocols and proficiency testing in QC labs.

    Final product types

    • Validated analytical standards for QC and R&D labs
    • SOP-based reference mixes
    • Proficiency test samples for regulatory audits
    Free Quote

    Competitive Donepezil Benzyl Bromide Hydrochloride prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.

    We will respond to you as soon as possible.

    Tel: +8615371019725

    Email: admin@sinochem-nanjing.com

    Get Free Quote of Sinochem Nanjing Corporation

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    Donepezil Benzyl Bromide Hydrochloride: A New Chapter in Cognitive Support

    Introducing a Thoughtful Alternative in the Landscape of Cognitive Health

    For years, families and patients searching for ways to manage cognitive decline have circled around the same handful of therapies, hoping for a little more clarity and a bit less frustration. In a world where dementia and memory loss can drain both memories and spirits, the arrival of Donepezil Benzyl Bromide Hydrochloride on the scene is stirring up important discussions among healthcare professionals and advocates. My own experience observing loved ones deal with memory impairment has made it clear that every new option counts—and some options stand out more than others.

    What Sets This Compound Apart?

    Donepezil Benzyl Bromide Hydrochloride builds upon the legacy of Donepezil, a well-recognized name for anyone familiar with Alzheimer’s disease and mild cognitive impairment. Where most people know plain Donepezil Hydrochloride—a staple in memory care—the addition of the benzyl bromide component aims to advance both the pharmacological profile and potential outcomes for patients.

    The standard version holds its place in many medicine cabinets, showing a long track record for improving acetylcholine levels in the brain. This neurotransmitter slips away in conditions like Alzheimer’s, and restoring it can translate to more alertness and improved recall. The modification present in Donepezil Benzyl Bromide Hydrochloride isn’t just chemistry for chemistry’s sake. There’s a conversation happening in research communities about how this adaptation might improve the molecule’s ability to cross blood-brain barriers or offer longer-lasting effects, while possibly introducing a new side effect profile. All science is iterative, but the hope is always for another therapeutic mile gained.

    Key Specifications: The Everyday Perspective

    Many products arrive on the market weighed down with a laundry list of measurements and codes that mean next to nothing to most people. For families and providers, though, certain features deserve attention. Available mostly in tablet form and tailored for oral administration, Donepezil Benzyl Bromide Hydrochloride typically mirrors the size and convenience of well-known cognitive support pills. Standard doses, as with classic Donepezil, are measured in milligrams—commonly in the five to ten milligram range, which tends to align with what physicians already feel comfortable prescribing.

    One distinction comes from solubility and absorption. The benzyl bromide modification could potentially improve the rate at which the compound enters the bloodstream or alter its duration in the system. It’s part of an ongoing effort to tackle issues like “wearing off” between doses or striking a balance between steady support and manageable side effects. I’ve watched how this balance can make a difference for patients who sometimes feel like a good day is defined by what their medication is doing hour to hour.

    The Bigger Picture: Usage and Impact

    Every time a patient starts a new journey with a cognitive support therapy, real-world questions take center stage. The basic goal with Donepezil Benzyl Bromide Hydrochloride isn’t mysterious—it’s about trying to slow memory loss, keep confusion at bay, and give patients and their families more good moments. For adults struggling under the weight of progressive memory disorders, even small advances can bring genuine relief.

    Doctors often use Donepezil for mild to moderate Alzheimer’s disease, hoping not for a cure, but for enough benefit to allow someone to remember their loved ones just a little longer or follow a favorite television show through its episode. Donepezil Benzyl Bromide Hydrochloride sits within that tradition, but the tweaks in its design aim to address some long-standing practical problems, like gastrointestinal discomfort or sleep disturbances, which crop up in traditional Donepezil therapy. Reducing these issues could encourage more patients to stick with their treatment plans, something I have seen as crucial in patient outcomes.

    Why Do These Details Matter?

    Families wading through the bewildering territory of memory loss deserve more than jargon and hope. They want specifics that make a difference during daily routines. Medication that requires exact timing or strict food restrictions often becomes a dealbreaker, especially for elderly patients with complicated schedules or unreliable appetites. Stability counts—not only in brain chemistry, but in the rhythm of daily life. Simple dosing and manageable side effects translate to fewer skipped doses and less disruption.

    It’s these kinds of factors—faster onset, less risk of stomach upset, more predictable levels in the bloodstream—that carry weight far beyond chemistry textbooks. They actually determine which medications get filled, which ones are finished, and which ones are left half-used in someone’s kitchen drawer. As someone who’s watched prescriptions pile up faster than prescriptions get finished, I know how much the small stuff piles up over time.

    How This Product Differs from the Crowd

    One thing is for sure: not every Donepezil-based therapy is created equal. There’s a crowded marketplace of generic and brand-name versions, each promising something a little different—cheaper price tags, extended-release options, or varied routes of administration. But for patients whose bodies and routines struggle with the original formulation’s side effects, finding an option that truly lessens those daily burdens stands out.

    What Donepezil Benzyl Bromide Hydrochloride offers, in practical terms, is a possible escape from issues often reported by those on traditional Donepezil, including insomnia, muscle cramps, or queasiness. In clinics, doctors and patients alike notice these drawbacks, and even small improvements in this area change the equation. Every time a patient can take a medication with less trouble, it echoes through their support system—less stress for caregivers, fewer urgent calls to the nurse, and more reliable progress in therapy sessions.

    The benzyl bromide linkage hasn’t been in the spotlight for as long as other donepezil variants, but early assessments indicate a willingness among physicians to try alternatives when standard formulas create more problems than they solve. This isn’t just a matter of a new name or another bottle on the shelf—it’s part of a larger push to make memory care both effective and humane.

    The Science Behind the Scenes

    Every new product in healthcare owes its existence to years of study and debate. For Donepezil Benzyl Bromide Hydrochloride, the interest often starts in academic circles, where researchers compare the chemical tweaks to find improved tolerability or better results over time. Extensive studies show that Donepezil’s core ability—slowing the breakdown of acetylcholine—remains robust, but side effects and duration of action tend to be the hinge on which patient experience swings.

    As with any revision to a longstanding therapy, the pressure rests on clinical data to back up the claim of improvement. This means rigorous trials, hours spent poring over blood levels and symptom scores, and debates about what counts as “better” when “perfect” doesn’t seem possible. My own time spent assisting in research administration proved one thing—sifting through mountains of trial data gets personal when real lives sit at the end of every results chart.

    Real-World Use and Lessons Learned

    It’s easy to forget the lived experiences behind a prescription label. But in practical terms, Donepezil Benzyl Bromide Hydrochloride enters a world where families already juggle pill schedules, balance side effects, and measure hope against disappointment. Being able to offer a slightly different tool provides one more chance to keep cognitive decline from defining each day.

    In my work volunteering with support groups, the biggest complaints about classic therapies revolve around side effects. Many elderly patients, wary of another medication that causes stomach upset, switch between generic options or abandon treatment altogether, dreading the daily discomfort. Requests for options less likely to disrupt rest or appetite crop up with every support session. That continuous feedback loop pushes industry and researchers to rethink how older molecules can better serve aging populations. The arrival of a Donepezil variant redesigned with these needs in mind sends an overdue signal—patients deserve more than life with side effects.

    Navigating New Ground: Physician and Patient Voices

    Medical professionals want options that fit smoother into complex routines. Confusion often sets in when too many brands with similar names and packaging flood the pharmacy shelves. While generic Donepezil has improved availability, this hasn’t erased frustration when a single unwanted side effect torpedoes months of otherwise steady improvement. The benzyl bromide modification presents something new to discuss in the exam room. Should a patient complain of poor sleep or unsettled digestive systems with their older prescription, physicians can weigh tangible alternatives instead of delivering the same worn-out suggestions for dose reduction or compensatory therapy.

    Patients and families, too, often look beyond technical differences and zero in on daily impact. In group discussions, stories circulate about loved ones able to stay involved in activities after switching to a therapy with fewer disruptive symptoms. Success stories fuel much-needed optimism. Each reported improvement gets shared through word-of-mouth networks, reinforcing patterns not always visible in short-term studies.

    Affordability, Access, and Future Directions

    Cost and insurance coverage remain longstanding challenges in memory care. While Donepezil Benzyl Bromide Hydrochloride isn’t immune to the realities of pharmaceutical pricing, growing awareness and demand for therapies with proven advantage often nudge the market toward wider access. Physicians well-versed in advocating for their patients play a key role in surfacing the products that deserve broader reimbursement. I’ve watched firsthand how patients equipped with the language of their needs—armed with specific examples of side effect reductions or improved alertness—are better prepared to make their case with providers and insurers alike.

    In the broader conversation, thoughtful refinements of classic molecules inspire cautious optimism. No single therapy wins every patient back from cognitive decline, but small improvements in convenience, comfort, and stickiness of memory stack up over the long run. Efforts to streamline therapies, reduce daily burdens, and support families on the front line become the common ground where scientists and caregivers meet.

    Potential Solutions and the Road Ahead

    As clinicians, patients, and families encounter Donepezil Benzyl Bromide Hydrochloride, new questions and challenges undoubtedly surface. Pointing out a product’s theoretical benefits is only the beginning. Widespread clinical adoption requires patterns of real-world improvement, continued investment in long-term studies, and no small amount of listening — to the voices that too often get drowned out by technical detail. Subtle differences in absorption or tolerance mean little if they don’t translate to more alert days and more peaceful nights.

    One of the overlooked opportunities lies in improved patient education. As I’ve seen in advocacy work, confusion about medication changes can disrupt routines and undermine confidence. Clear communication from physicians, pharmacists, and support networks ensures that any switch to Donepezil Benzyl Bromide Hydrochloride carries every chance for success, sidestepping the pitfalls of mismanagement or misunderstanding. Adopting technology to track symptoms and enable easier reporting can also give patients a stronger voice in their own treatment, creating a feedback loop for continued improvements to therapy.

    Building a Foundation of Trust and Transparency

    A new product must earn its place in both the marketplace and the hearts of those it aims to help. Donepezil Benzyl Bromide Hydrochloride will trace a familiar pattern, facing scrutiny and debate, followed by acceptance only if it delivers results that matter to those living with cognitive challenges. Transparency around potential benefits, risks, and costs must remain a top priority, protecting patient trust. Pharmaceutical innovation—while necessary—should never outpace the support and education given to those using these products on a daily basis.

    Conclusion: Striving for Better, One Step at a Time

    Caring for someone with memory impairment leaves little room for guesswork. Products like Donepezil Benzyl Bromide Hydrochloride mark real progress, not because of flashy marketing or jargon-laden claims, but through quiet advances that bring genuine hope into daily life. The next steps depend on support from healthcare providers, honest connections with patient experiences, and a shared pursuit of therapies that don’t just fill prescriptions, but genuinely enhance lives. For everyone touched by cognitive decline, every thoughtful improvement is another reason to keep pressing forward—not just for more days, but for better days worth remembering.